PWW

Portfolio AI Insights

pww.comNVIDIA Corporation Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-08-2024 10:30 AM - NasdaqGS:NVDA

NasdaqGS:NVDA

Kimberly Powell [Vice President of Healthcare] đź’¬

Kimberly Powell, Vice President of Healthcare at NVIDIA, presented at the J.P. Morgan 42nd Annual Healthcare Conference on January 8, 2024. Below is a detailed summary of her presentation:

Key Points

  1. Introduction

    • Honored to present alongside healthcare leaders.
    • Highlighted the importance of technology in healthcare.

  2. Safe Harbor Statement

    • Reminded attendees of the forward-looking statements disclaimer.

  3. Accelerated Computing and AI

    • NVIDIA drives two computing transitions: accelerated computing and AI.
    • AI involves more than GPUs; it addresses full-stack data center problems.
    • Accelerated computing and AI enable generative AI applications like ChatGPT.

  4. Digital Biology Era

    • Enabled by accelerated computing and generative AI.
    • Examples include the $100 genome and new omics fields.

  5. Deepcell’s REM-I Platform

    • New platform for cell imaging, sorting, and high-dimensional analysis.
    • Uses generative AI algorithms and NVIDIA GPUs for real-time cell analysis.

  6. Spatial Genomics

    • Study of single-cell genomics in 2D and 3D.
    • NanoString's CosMx system visualizes 600 gene and protein targets per cell, generating 6 TB of data per sample.

  7. Digitization of Biology and Generative AI

    • Allows representation of biology and chemistry in computers.
    • New applications in docking algorithms, pathogenicity prediction, and antibiotic discovery.

  8. Computer-Aided Drug Discovery (CAD) Industry

    • Historically, computation and mathematics have advanced drug discovery.
    • Generative AI is igniting exponential expansion in the CAD industry.
    • NVIDIA's domain-specific computing platform, NVIDIA Clara, accelerates the next generation of CAD.

  9. BioNeMo Platform

    • Generative AI platform for developing, customizing, and deploying foundation models for drug discovery.
    • Provides scalable and optimized training on proprietary data.
    • Offers a growing collection of pretrained models.
    • Models from NVIDIA, open source, and NVIDIA partners.

  10. Amgen Collaboration

    • Amgen adopts NVIDIA DGX Cloud and BioNeMo.
    • Building supercomputer Freyja in Iceland to analyze 200 PB of de-identified human data.

  11. BioNeMo Beta Launch

    • Advancing into beta with adoption by leading CAD makers.
    • Provides enterprise-grade APIs for scalable and stable models.
    • Optimized models deliver 7x faster throughput and cost savings.

  12. Recursion Partnership

    • Announces Phenom-Beta, the first partner model in BioNeMo.
    • Vision transformer model for cellular data in target and hit discovery.

  13. NVIDIA’s MolMIM Foundation Model

    • Uses a large language model for controlled molecular generation.
    • Achieves state-of-the-art constrained generation with multiple objectives.
    • Enhances generative performance in validity, uniqueness, and novelty.

  14. Next Generation of Drug Discovery

    • Diverse ecosystem of next-generation CAD platforms.
    • Specializes in different disease focuses, therapeutic classes, and discovery/design methods.

  15. Investment Strategy

    • Invests in companies using, enhancing, and expanding NVIDIA's platform.
    • Focuses on data-first, AI-heavy, tech-first companies.
    • Supports companies combining machine learning with physics simulations.

  16. 2023 Highlights

    • Collaborations with Amgen, Medtronic, and Genentech.
    • Medtronic's GI Genius AI-assisted colonoscopy tool.
    • Multiyear AI research collaboration with Genentech.

  17. Market Opportunity

    • Billions of wearable devices and medical AI assistance.
    • Generative AI transforming healthcare into a large technology industry.

  18. Conclusion

    • Generative AI is a transformative technology for healthcare.
    • NVIDIA's decade-long preparation and deep domain expertise.
    • Excitement about technology's role in healthcare.

Question and Answer Session

  1. Transition from Lead Generation to Regulated Software/Hardware

    • NVIDIA builds essential components for companies that handle regulation and validation.
    • Focuses on accelerating computing and AI to make them tools for the industry's methods.

  2. Capacity to Meet Exponential Growth in Demand

    • Challenges include scaling to meet the demand for generative AI inference.
    • NVIDIA focuses on improving computing efficiency through benchmarks and software optimization.

  3. Impact on Drug Discovery Ecosystem

    • Similar to the consolidation in computer-aided design for chips.
    • Personalized medicine will likely expand the ecosystem rather than collapse it.

  4. Approach to Complex Biologics

    • Protein-focused due to their attractive traits for drugs.
    • Work on complex biologics is heavily focused in the AI market.

  5. Data Marketplace or Collaborative Ecosystem

    • Open to discussions about a data marketplace or collaborative ecosystem.

    • Currently focused on making AI capabilities widely available.

Feedback